Bilateral posterior RION after concomitant radiochemotherapy with temozolomide in a patient with glioblastoma multiforme: A case report

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Schreiber, Stefanie ^a   Prox Vagedes, Vanessa ^b   Elolf, Erck ^a   Brueggemann, Ines ^a   Gademann, Guenther ^a   Galazky, Imke ^a   Bartels, Claudius ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE;

ADULT; ARTICLE; BLINDNESS; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CASE REPORT; CONCENTRATION (PARAMETERS); CONTRAST ENHANCEMENT; DISEASE ASSOCIATION; DISEASE SEVERITY; EYE EXAMINATION; FEMALE; GLIOBLASTOMA; HEADACHE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KARNOFSKY PERFORMANCE STATUS; MULTIPLE CYCLE TREATMENT; NEUROIMAGING; NEUROSURGERY; OPTIC CHIASM; OPTIC NERVE DISEASE; RADIATION DOSE; RADIOSENSITIZATION; SELF MEDICATION; TREATMENT DURATION; TUMOR GROWTH; VISUAL ACUITY; VISUAL HALLUCINATION; DRUG THERAPY; HYPERICUM; METABOLISM; METHODOLOGY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE; RADIATION; RADIATION INJURY; RADIOTHERAPY;

ANTINEOPLASTIC AGENTS, ALKYLATING; DACARBAZINE; DRUG THERAPY; FEMALE; GLIOBLASTOMA; HUMANS; HYPERICUM; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; OPTIC NERVE; OPTIC NERVE DISEASES; RADIATION; RADIATION INJURIES; RADIOTHERAPY;

EID: 77957194006     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-520     Document Type: Article

References (27)

1. Danesh-Meyer HV. Radiation-induced optic neuropathy. J Clin Neurosci 2008, 15:95-100. 10.1016/j.jocn.2007.09.004, 18068989.
2. Bhandare N, Monroe AT, Morris CG, Bhatti MT, Mendenhall WM. Does altered fractionation influence the risk of radiation-induced optic neuropathy?. Int J Radiat Oncol Biol Phys 2005, 62:1070-1077.
3. Harris JR, Levene MB. Visual complications following irradiation for pituitary adenomas and craniopharyngiomas. Radiology 1976, 120:167-171.
4. Demizu Y, Murakami M, Miyawaki D, Niwa Y, Akagi T, Sasaki R, Terashima K, Suga D, Kamae I, Hishikawa Y. Analysis of Vision Loss Caused by Radiation-Induced Optic Neuropathy After Particle Therapy for Head-and-Neck and Skull-Base Tumors Adjacent to Optic Nerves. Int J Radiat Oncol Biol Phys 2009, 75:1487-1492.
5. Guy J, Mancuso A, Beck R, Moster ML, Sedwick LA, Quisling RG, Rhoton AL, Protzko EE, Schiffman J. Radiation-induced optic neuropathy: a magnetic resonance imaging study. J Neurosurg 1991, 74:426-432. 10.3171/jns.1991.74.3.0426, 1993908.
6. Griffin JD, Garnick MB. Eye toxicity of cancer chemotherapy: a review of the literature. Cancer 1981, 48:1539-1549. 10.1002/1097-0142(19811001)48:7<1539::AID-CNCR2820480713>3.0.CO;2-B, 7026021.
7. Sanderson PA, Kuwabara T, Cogan DG. Optic neuropathy presumably caused by vincristine therapy. Am J Ophthalmol 1976, 81:146-150.
8. Chang JE, Khuntia D, Robins HI, Mehta MP. Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme. Clin Adv Hematol Oncol 2007, 5:894-15.
9. Lai A, Filka E, McGibbon B, Nghiemphu PL, Graham C, Yong WH, Mischel P, Liau LM, Bergsneider M, Pope W, Selch M, Cloughesy T. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 2008, 71:1372-1380.
10. Karnofsky DA, Burchenal JH, Armistead GC, Southam CM, Bernstein JL, Craver LF, Rhoads CP. Triethylene melamine in the treatment of neoplastic disease; a compound with nitrogen-mustardlike activity suitable for oral and intravenous use. AMA Arch Intern Med 1951, 87:477-516.
11. Hudgins PA, Newman NJ, Dillon WP, Hoffman JC. Radiation-induced optic neuropathy: characteristic appearances on gadolinium-enhanced MR. AJNR Am J Neuroradiol 1992, 13:235-238.
12. Young WC, Thornton AF, Gebarski SS, Cornblath WT. Radiation-induced optic neuropathy: correlation of MR imaging and radiation dosimetry. Radiology 1992, 185:904-907.
13. Miller NR. Radiation-induced optic neuropathy: still no treatment. Clin Experiment Ophthalmol 2004, 32:233-235. 10.1111/j.1442-9071.2004.00809.x, 15180831.
14. Theodossiou TA, Hothersall JS, De Witte PA, Pantos A, Agostinis P. The multifaceted photocytotoxic profile of hypericin. Mol Pharm 2009, 6:1775-1789. 10.1021/mp900166q, 19739671.
15. Ferenc P, Solar P, Kleban J, Mikes J, Fedorocko P. Down-regulation of Bcl-2 and Akt induced by combination of photoactivated hypericin and genistein in human breast cancer cells. J Photochem Photobiol B 2010, 98:25-34. 10.1016/j.jphotobiol.2009.10.004, 19932626.
16. Durkacz BW, Omidiji O, Gray DA, Shall S. (ADP-ribose)n participates in DNA excision repair. Nature 1980, 283:593-596. 10.1038/283593a0, 6243744.
17. Boulton S, Pemberton LC, Porteous JK, Curtin NJ, Griffin RJ, Golding BT, Durkacz BW. Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. Br J Cancer 1995, 72:849-856. 2034052, 7547230.
18. Russo AL, Kwon HC, Burgan WE, Carter D, Beam K, Weizheng X, Zhang J, Slusher BS, Chakravarti A, Tofilon PJ, Camphausen K. In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016. Clin Cancer Res 2009, 15:607-612. 10.1158/1078-0432.CCR-08-2079, 19147766.
19. Boyar MS, Hesdorffer M, Keohan ML, Jin Z, Taub RN. Phase II Study of Temozolomide and Thalidomide in Patients with Unresectable or Metastatic Leiomyosarcoma. Sarcoma 2008, 2008:412503. 10.1155/2008/412503, 2583339, 19043564.
20. Rosso L, Brock CS, Gallo JM, Saleem A, Price PM, Turkheimer FE, Aboagye EO. A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients. Cancer Res 2009, 69:120-127. 10.1158/0008-5472.CAN-08-2356, 19117994.
21. Datta R, Banach D, Kojima H, Talanian RV, Alnemri ES, Wong WW, Kufe DW. Activation of the CPP32 protease in apoptosis induced by 1-beta-D-arabinofuranosylcytosine and other DNA-damaging agents. Blood 1996, 88:1936-1943.
22. Chmura SJ, Mauceri HJ, Advani S, Heimann R, Beckett MA, Nodzenski E, Quintans J, Kufe DW, Weichselbaum RR. Decreasing the apoptotic threshold of tumor cells through protein kinase C inhibition and sphingomyelinase activation increases tumor killing by ionizing radiation. Cancer Res 1997, 57:4340-4347.
23. Robins HI, Won M, Seiferheld WF, Schultz CJ, Choucair AK, Brachman DG, Demas WF, Mehta MP. Phase 2 trial of radiation plus high-dose tamoxifen for glioblastoma multiforme: RTOG protocol BR-0021. Neuro Oncol 2006, 8:47-52. 10.1215/S1522851705000311, 1871929, 16443947.
24. Karioti A, Bilia AR. Hypericins as potential leads for new therapeutics. Int J Mol Sci 2010, 11:562-594. 10.3390/ijms11020562, 2852855, 20386655.
25. Wong CS, Van der Kogel AJ. Mechanisms of radiation injury to the central nervous system: implications for neuroprotection. Mol Interv 2004, 4:273-284. 10.1124/mi.4.5.7, 15471910.
26. Fox SW, Lyon D, Farace E. Symptom clusters in patients with high-grade glioma. J Nurs Scholarsh 2007, 39:61-67. 10.1111/j.1547-5069.2007.00144.x, 17393967.
27. Linde K. St. John's wort - an overview. Forsch Komplementmed 2009, 16:146-155. 10.1159/000209290, 19657198.